World Pharma Today

The US Food and Drug Administration has awarded three additional Commissioner’s National Priority Vouchers under its accelerated regulatory framework, targeting companies developing psychedelic-based therapies. The move follows President Donald Trump’s April 18 executive order aimed at advancing mental health treatment innovation. While the agency did not officially disclose ...

MSD has entered into a multi-year agreement with Google Cloud valued at up to $1 billion, enabling widespread deployment of advanced artificial intelligence tools across its global workforce of 75,000 employees. The collaboration will integrate Google Cloud’s agentic AI capabilities throughout the organisation, spanning research and development, manufacturing, commercial oper...

Choosing a gene expression system is one of the earliest and most consequential manufacturing decisions a biotech founder will make yet it is often made without fully understanding what is at stake. This article breaks down the key expression platforms used in biologic drug development, what differentiates them technically and commercially, and why the choice you make now wil...

Royalties, milestone payments, and license fees are often treated as the cost of doing business in biopharma. But for early-stage biotech companies building toward an IND, these obligations can quietly reshape financial models, complicate investor conversations, and create downstream deal terms that are difficult to unwind. Here is what founders need to know.

AbbVie has outlined plans to build a major new manufacturing facility in Durham, committing $1.4 billion to what will become its largest single-campus capital investment to date. The project, spread across 185 acres, is expected to generate more than 730 jobs and will support the production of medicines across the company’s immunology, neuroscience and oncology […]